Qube Research & Technologies LTD Arrowhead Pharmaceuticals, Inc. Transaction History

Qube Research & Technologies LTD

$65.7 Billion
Q3 2024

A detailed history of Qube Research & Technologies LTD transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 80,356 shares of ARWR stock, worth $1.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

80,356

Holding current value

$1.69 Million

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.36 - $29.54 $1.56 Million - $2.37 Million	80,356 New	80,356 $1.56 Million
Q3 2023 Nov 13, 2023	BUY	$26.2 - $36.08 $929,130 - $1.28 Million	35,463 Added 98.25%	71,558 $1.92 Million
Q2 2023 Aug 14, 2023	SELL	$25.16 - $41.38 $315,078 - $518,201	-12,523 Reduced 25.76%	36,095 $1.29 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $1.15 Million - $1.87 Million	48,618 New	48,618 $1.23 Million
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $320,307 - $583,330	-11,526 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$39.62 - $69.97 $456,660 - $806,474	11,526 New	11,526 $530,000
Q3 2021 Nov 12, 2021	SELL	$58.38 - $84.96 $1.37 Million - $2 Million	-23,520 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$62.15 - $90.32 $1.46 Million - $2.12 Million	23,520 New	23,520 $1.95 Million
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $110,139 - $338,133	-5,357 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$28.14 - $73.01 $150,745 - $391,114	5,357 New	5,357 $340,000

Others Institutions Holding ARWR

# of Institutions

295

Shares Held

91.1M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.23B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Account

Qube Research & Technologies LTD Arrowhead Pharmaceuticals, Inc. Transaction History